Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Gilda Schmidt; Christoph Gerlinger; Ingolf Juhasz-Böss; Elmar Stickeler; Achim Rody; Cornelia Liedtke; Pauline Wimberger; Theresa Link; Eberhard Müller; Tanja Fehm; Manuela Abel; Stefan Stein; Rainer Bohle; Jan Endrikat; Erich-Franz Solomayer

doi:10.1007/s00432-016-2146-z

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Gilda Schmidt, Christoph Gerlinger, Ingolf Juhasz-Böss, Elmar Stickeler, Achim Rody, Cornelia Liedtke, Pauline Wimberger, Theresa Link, Eberhard Müller, Tanja Fehm, Manuela Abel, Stefan Stein, Rainer Bohle, Jan Endrikat, Erich-Franz Solomayer

Klinik für Frauenheilkunde und Geburtshilfe

15 Zitate (Scopus)

Abstract

PURPOSE: Triple-negative breast cancer (TNBC) is characterized by a strong heterogeneity with regard to tumour biology as well as in the clinical course of the disease. This study aimed to analyse whether there are any prognostic factors enabling prediction of the clinical outcome in patients with TNBC. Particularly, the impact of Her2-neu score 0 versus Her2-neu score 1 and 2 on survival was investigated.

MATERIALS AND METHODS: We retrospectively studied a cohort of 1013 patients with TNBC, diagnosed at seven hospitals between May 2002 and February 2015. We studied the impact of Her2-neu scores (0 vs. 1 or 2 with negative FISH) on disease-free survival (DFS) and overall survival (OS).

RESULTS: 1013 patients were included in this study. 447 (44.13 %) of them had a T2-4 tumour. A total of 314 (31.00 %) were nodal-positive and 714 (70.48 %) had high-grade tumours. The Her2-neu score of all participating patients was determined. 588 (58.05 %) of them had a Her2-neu score 0, and 425 (41.95 %) had a score of 1 or 2. This study shows that TNBC patients with a Her2-neu score 0 had a significantly poorer outcome regarding DFS (p = 0.0001) and OS (p = 0.0051) compared to a score of 1 or 2. In contrast, grading did not seem to have any prognostic value for women with TNBC.

CONCLUSION: The Her2-neu score 0 might be considered as an innovative prognostic factor for patients with TNBC indicating poor clinical outcome.

Originalsprache	Englisch
Zeitschrift	Journal of Cancer Research and Clinical Oncology
Jahrgang	142
Ausgabenummer	6
Seiten (von - bis)	1369-76
Seitenumfang	8
ISSN	0171-5216
DOIs	https://doi.org/10.1007/s00432-016-2146-z
Publikationsstatus	Veröffentlicht - 06.2016

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.1007/s00432-016-2146-z

Zitieren

Schmidt, G., Gerlinger, C., Juhasz-Böss, I., Stickeler, E., Rody, A., Liedtke, C., Wimberger, P., Link, T., Müller, E., Fehm, T., Abel, M., Stein, S., Bohle, R., Endrikat, J., & Solomayer, E.-F. (2016). Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology, 142(6), 1369-76. https://doi.org/10.1007/s00432-016-2146-z

@article{e076d51335684007bd5d48721f264b98,

title = "Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer",

abstract = "PURPOSE: Triple-negative breast cancer (TNBC) is characterized by a strong heterogeneity with regard to tumour biology as well as in the clinical course of the disease. This study aimed to analyse whether there are any prognostic factors enabling prediction of the clinical outcome in patients with TNBC. Particularly, the impact of Her2-neu score 0 versus Her2-neu score 1 and 2 on survival was investigated.MATERIALS AND METHODS: We retrospectively studied a cohort of 1013 patients with TNBC, diagnosed at seven hospitals between May 2002 and February 2015. We studied the impact of Her2-neu scores (0 vs. 1 or 2 with negative FISH) on disease-free survival (DFS) and overall survival (OS).RESULTS: 1013 patients were included in this study. 447 (44.13 \%) of them had a T2-4 tumour. A total of 314 (31.00 \%) were nodal-positive and 714 (70.48 \%) had high-grade tumours. The Her2-neu score of all participating patients was determined. 588 (58.05 \%) of them had a Her2-neu score 0, and 425 (41.95 \%) had a score of 1 or 2. This study shows that TNBC patients with a Her2-neu score 0 had a significantly poorer outcome regarding DFS (p = 0.0001) and OS (p = 0.0051) compared to a score of 1 or 2. In contrast, grading did not seem to have any prognostic value for women with TNBC.CONCLUSION: The Her2-neu score 0 might be considered as an innovative prognostic factor for patients with TNBC indicating poor clinical outcome.",

author = "Gilda Schmidt and Christoph Gerlinger and Ingolf Juhasz-B{\"o}ss and Elmar Stickeler and Achim Rody and Cornelia Liedtke and Pauline Wimberger and Theresa Link and Eberhard M{\"u}ller and Tanja Fehm and Manuela Abel and Stefan Stein and Rainer Bohle and Jan Endrikat and Erich-Franz Solomayer",

year = "2016",

month = jun,

doi = "10.1007/s00432-016-2146-z",

language = "English",

volume = "142",

pages = "1369--76",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

Schmidt, G, Gerlinger, C, Juhasz-Böss, I, Stickeler, E, Rody, A, Liedtke, C, Wimberger, P, Link, T, Müller, E, Fehm, T, Abel, M, Stein, S, Bohle, R, Endrikat, J & Solomayer, E-F 2016, 'Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer', Journal of Cancer Research and Clinical Oncology, Jg. 142, Nr. 6, S. 1369-76. https://doi.org/10.1007/s00432-016-2146-z

TY - JOUR

T1 - Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

AU - Schmidt, Gilda

AU - Gerlinger, Christoph

AU - Juhasz-Böss, Ingolf

AU - Stickeler, Elmar

AU - Rody, Achim

AU - Liedtke, Cornelia

AU - Wimberger, Pauline

AU - Link, Theresa

AU - Müller, Eberhard

AU - Fehm, Tanja

AU - Abel, Manuela

AU - Stein, Stefan

AU - Bohle, Rainer

AU - Endrikat, Jan

AU - Solomayer, Erich-Franz

PY - 2016/6

Y1 - 2016/6

N2 - PURPOSE: Triple-negative breast cancer (TNBC) is characterized by a strong heterogeneity with regard to tumour biology as well as in the clinical course of the disease. This study aimed to analyse whether there are any prognostic factors enabling prediction of the clinical outcome in patients with TNBC. Particularly, the impact of Her2-neu score 0 versus Her2-neu score 1 and 2 on survival was investigated.MATERIALS AND METHODS: We retrospectively studied a cohort of 1013 patients with TNBC, diagnosed at seven hospitals between May 2002 and February 2015. We studied the impact of Her2-neu scores (0 vs. 1 or 2 with negative FISH) on disease-free survival (DFS) and overall survival (OS).RESULTS: 1013 patients were included in this study. 447 (44.13 %) of them had a T2-4 tumour. A total of 314 (31.00 %) were nodal-positive and 714 (70.48 %) had high-grade tumours. The Her2-neu score of all participating patients was determined. 588 (58.05 %) of them had a Her2-neu score 0, and 425 (41.95 %) had a score of 1 or 2. This study shows that TNBC patients with a Her2-neu score 0 had a significantly poorer outcome regarding DFS (p = 0.0001) and OS (p = 0.0051) compared to a score of 1 or 2. In contrast, grading did not seem to have any prognostic value for women with TNBC.CONCLUSION: The Her2-neu score 0 might be considered as an innovative prognostic factor for patients with TNBC indicating poor clinical outcome.

AB - PURPOSE: Triple-negative breast cancer (TNBC) is characterized by a strong heterogeneity with regard to tumour biology as well as in the clinical course of the disease. This study aimed to analyse whether there are any prognostic factors enabling prediction of the clinical outcome in patients with TNBC. Particularly, the impact of Her2-neu score 0 versus Her2-neu score 1 and 2 on survival was investigated.MATERIALS AND METHODS: We retrospectively studied a cohort of 1013 patients with TNBC, diagnosed at seven hospitals between May 2002 and February 2015. We studied the impact of Her2-neu scores (0 vs. 1 or 2 with negative FISH) on disease-free survival (DFS) and overall survival (OS).RESULTS: 1013 patients were included in this study. 447 (44.13 %) of them had a T2-4 tumour. A total of 314 (31.00 %) were nodal-positive and 714 (70.48 %) had high-grade tumours. The Her2-neu score of all participating patients was determined. 588 (58.05 %) of them had a Her2-neu score 0, and 425 (41.95 %) had a score of 1 or 2. This study shows that TNBC patients with a Her2-neu score 0 had a significantly poorer outcome regarding DFS (p = 0.0001) and OS (p = 0.0051) compared to a score of 1 or 2. In contrast, grading did not seem to have any prognostic value for women with TNBC.CONCLUSION: The Her2-neu score 0 might be considered as an innovative prognostic factor for patients with TNBC indicating poor clinical outcome.

U2 - 10.1007/s00432-016-2146-z

DO - 10.1007/s00432-016-2146-z

M3 - Journal articles

C2 - 27008006

SN - 0171-5216

VL - 142

SP - 1369

EP - 1376

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 6

ER -

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Abstract

UN SDGs

Dokumente

Fingerprint

Zitieren